QuantaMatrix Passes Preliminary Review for KOSDAQ Listing... Full-Scale IPO 추진

[Asia Economy Reporter Kum Bo-ryeong] Microbial diagnostics specialist company 'QuantaMatrix' is set to actively pursue an initial public offering (IPO) after passing the preliminary review for listing on KOSDAQ.

QuantaMatrix announced on the 26th that it completed the preliminary review approval process at the Korea Exchange on the 25th. In the technology evaluation conducted last November, it received an A grade from both the Korea Technology Finance Corporation and Korea Enterprise Data, and on April 14th, it submitted the preliminary review application to the Korea Exchange.

QuantaMatrix is a microbial diagnostics specialist company that commercialized the rapid antimicrobial susceptibility testing system 'dRAST' domestically and in Europe. dRAST is a product that can improve the survival rate of emergency sepsis patients.

A QuantaMatrix official explained, "Sepsis, a systemic inflammatory response syndrome caused by bacterial infection, is a very critical emergency disease where the patient's survival rate decreases by 7-9% every hour after confirmation. Despite various diagnostic and treatment methods currently applied worldwide, the mortality rate remains a frightening 30-40%. For sepsis treatment, it is necessary to apply the optimal antimicrobial agent suitable for each patient as quickly and accurately as possible, even by one hour, and dRAST provides that solution."

The commercialization of dRAST not only increases patient survival rates but also significantly reduces the misuse and overprescription of inappropriate antimicrobial agents, fundamentally preventing the spread of superbugs. Additionally, it is meaningful in that it can greatly reduce the socioeconomic costs required for treating severe sepsis patients.

QuantaMatrix has already completed certification procedures for dRAST in both domestic and European markets. Major hospitals in eight European countries are already applying it in clinical settings. Furthermore, the company plans to commercialize various innovative diagnostic pipelines, including the rapid drug susceptibility testing product for tuberculosis (QDST), rapid culture-free bacterial identification product (QID), and early diagnosis product for Alzheimer's dementia.

Kwon Seong-hoon, CEO of QuantaMatrix, stated, "Through the listing, we will accelerate our business in Europe and focus on completing the various pipelines currently in progress."

This content was produced with the assistance of AI translation services.